Nottingham-based Clinical Research Organisation (CRO) XenoGesis has appointed Graham Trevitt as Director of External Projects.
Trevitt joins the company from Almac Discovery where he was Director of Medicinal Chemistry, responsible for medicinal chemistry strategy across all projects including integration of DMPK properties into the design and progression of compounds.
Trevitt will work closely with the XenoGesis team and clients to provide scientific leadership of client projects and consultative project management. He is also responsible for identifying ways in which the company can improve the science behind its work such as how it can refine its prediction of how compounds will behave in man.
In addition to Trevitt, XenoGesis has appointed Sally Stinson and Liz Rendall as Senior Research Scientists, plus Andrea O’Sullivan who joins as Office Administrator. Next month, Fay Davidson will be joining from Evotec as Research Scientist.
XenoGesis is a specialist CRO focusing on preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation.
